PL2739628T3 - Nowe makrocykle jako inhibitory czynnika xia - Google Patents

Nowe makrocykle jako inhibitory czynnika xia

Info

Publication number
PL2739628T3
PL2739628T3 PL12762427T PL12762427T PL2739628T3 PL 2739628 T3 PL2739628 T3 PL 2739628T3 PL 12762427 T PL12762427 T PL 12762427T PL 12762427 T PL12762427 T PL 12762427T PL 2739628 T3 PL2739628 T3 PL 2739628T3
Authority
PL
Poland
Prior art keywords
xia
cycles
factor inhibitors
new macro
macro
Prior art date
Application number
PL12762427T
Other languages
English (en)
Inventor
Donald J. Pinto
James R. Corte
Paul J. Gilligan
Tianan Fang
Ii Leon M. Smith
Yufeng Wang
Wu Yang
William R. Ewing
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL2739628T3 publication Critical patent/PL2739628T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12762427T 2011-08-05 2012-08-06 Nowe makrocykle jako inhibitory czynnika xia PL2739628T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515401P 2011-08-05 2011-08-05
EP12762427.8A EP2739628B1 (en) 2011-08-05 2012-08-06 Novel macrocycles as factor xia inhibitors

Publications (1)

Publication Number Publication Date
PL2739628T3 true PL2739628T3 (pl) 2017-11-30

Family

ID=46889416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12762427T PL2739628T3 (pl) 2011-08-05 2012-08-06 Nowe makrocykle jako inhibitory czynnika xia

Country Status (22)

Country Link
US (4) US9221818B2 (pl)
EP (1) EP2739628B1 (pl)
JP (1) JP6158181B2 (pl)
CN (1) CN103857681B (pl)
AR (1) AR088748A1 (pl)
BR (1) BR112014002202A2 (pl)
CA (1) CA2844254A1 (pl)
CY (1) CY1119281T1 (pl)
DK (1) DK2739628T3 (pl)
EA (1) EA024791B1 (pl)
ES (1) ES2635088T3 (pl)
HR (1) HRP20171122T1 (pl)
HU (1) HUE034487T2 (pl)
LT (1) LT2739628T (pl)
MX (1) MX345763B (pl)
PL (1) PL2739628T3 (pl)
PT (1) PT2739628T (pl)
RS (1) RS56244B1 (pl)
SI (1) SI2739628T1 (pl)
SM (1) SMT201700413T1 (pl)
TW (1) TW201311689A (pl)
WO (1) WO2013022818A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102834397B (zh) 2010-02-11 2016-02-03 百时美施贵宝公司 作为凝血因子xia抑制剂的大环化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
TWI586651B (zh) 2011-10-14 2017-06-11 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
IN2014CN02805A (pl) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2605824T3 (es) 2012-08-03 2017-03-16 Bristol-Myers Squibb Company Dihidropiridona como inhibidores del factor XIa
PT2880026T (pt) * 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
NZ707990A (en) 2012-10-12 2018-07-27 Bristol Myers Squibb Co Crystalline forms of a factor xia inhibitor
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
FR3010076B1 (fr) * 2013-09-02 2016-12-23 Centre Nat De La Rech Scient - Cnrs - Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques
NO2760821T3 (pl) 2014-01-31 2018-03-10
UY35971A (es) * 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3104703B1 (en) * 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
NO2721243T3 (pl) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN108026083B (zh) * 2015-06-19 2021-08-27 百时美施贵宝公司 作为因子xia抑制剂的二酰胺大环
EP3328851B1 (en) 2015-07-29 2020-04-22 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties
KR102729666B1 (ko) 2015-07-29 2024-11-12 브리스톨-마이어스 스큅 컴퍼니 비-방향족 P2' 기를 갖는 인자 XIa 신규 마크로사이클
EA202191548A1 (ru) 2015-10-01 2021-09-02 Байокрист Фармасьютикалз, Инк. Ингибиторы плазменного калликреина человека
CN108430471B (zh) 2015-10-29 2021-07-09 默沙东公司 因子XIa抑制剂
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
JP2019507167A (ja) 2016-03-02 2019-03-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害活性を有するジアミド大員環
US20190135761A1 (en) * 2016-05-10 2019-05-09 Solvay Sa Composition comprising 3-(haloalkyl or formyl)-1h-pyrazole-4-carboxylic acids or esters, its manufacture and its use for the preparation of carboxamides
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
EP3309143A1 (en) * 2016-10-17 2018-04-18 Solvay SA Method for producing fluoroformate compounds
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN107011275A (zh) * 2017-03-31 2017-08-04 深圳市众康动保科技有限公司 一种1,4,5‑三取代‑1,2,3‑三氮唑类化合物的合成方法
WO2019011166A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 大环酰胺化合物及其药物组合物和用途
EP3957638B1 (en) 2019-04-16 2025-01-08 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as xia factor inhibitor
US20220281868A1 (en) 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
CN112920005B (zh) * 2021-01-31 2022-06-14 上海李氏化学科技有限公司 一种(r)-3-(3-氯-2-氟苯)-4,5-二氢异噁唑-5-羧酸的制备方法
US12252497B2 (en) * 2021-05-05 2025-03-18 Revolution Medicines, Inc. Ras inhibitors
MX2023013085A (es) * 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
CN113336715B (zh) * 2021-08-04 2021-11-23 山东海利尔化工有限公司 一种含二氧戊环的三唑类化合物及其中间体的制备方法
MX2024003738A (es) 2021-10-01 2024-06-19 Nuvalent Inc Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
HRP20040280B1 (hr) 2001-09-21 2013-09-30 Bristol-Myers Squibb Company A Delaware (Usa) Corporation SPOJEVI KOJI SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
WO2007070826A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AR058380A1 (es) * 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
US20080099168A1 (en) 2006-10-26 2008-05-01 Kou-Chang Liu Soft and absorbent tissue products
CN101605779B (zh) 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
US8367709B2 (en) 2007-06-13 2013-02-05 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
CN102834397B (zh) * 2010-02-11 2016-02-03 百时美施贵宝公司 作为凝血因子xia抑制剂的大环化合物
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
IN2014CN02805A (pl) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
TWI586651B (zh) 2011-10-14 2017-06-11 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
PT2880026T (pt) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
ES2605824T3 (es) 2012-08-03 2017-03-16 Bristol-Myers Squibb Company Dihidropiridona como inhibidores del factor XIa
NZ707990A (en) 2012-10-12 2018-07-27 Bristol Myers Squibb Co Crystalline forms of a factor xia inhibitor
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Also Published As

Publication number Publication date
HRP20171122T1 (hr) 2017-10-06
JP2014521701A (ja) 2014-08-28
US9221818B2 (en) 2015-12-29
EP2739628B1 (en) 2017-06-07
US20170158712A1 (en) 2017-06-08
CN103857681B (zh) 2017-07-14
LT2739628T (lt) 2017-08-25
AR088748A1 (es) 2014-07-02
EA201490418A1 (ru) 2014-05-30
CY1119281T1 (el) 2018-02-14
SMT201700413T1 (it) 2017-11-15
HUE034487T2 (en) 2018-02-28
US10208068B2 (en) 2019-02-19
US20160068544A1 (en) 2016-03-10
JP6158181B2 (ja) 2017-07-05
EP2739628A1 (en) 2014-06-11
ES2635088T3 (es) 2017-10-02
DK2739628T3 (en) 2017-09-11
US20180148461A1 (en) 2018-05-31
SI2739628T1 (sl) 2017-08-31
WO2013022818A1 (en) 2013-02-14
CA2844254A1 (en) 2013-02-14
RS56244B1 (sr) 2017-11-30
CN103857681A (zh) 2014-06-11
MX345763B (es) 2017-02-15
US9611274B2 (en) 2017-04-04
EA024791B1 (ru) 2016-10-31
TW201311689A (zh) 2013-03-16
MX2014000831A (es) 2014-02-27
US9902742B2 (en) 2018-02-27
US20140221338A1 (en) 2014-08-07
PT2739628T (pt) 2017-08-02
BR112014002202A2 (pt) 2017-03-07

Similar Documents

Publication Publication Date Title
PL2739628T3 (pl) Nowe makrocykle jako inhibitory czynnika xia
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
PL2892900T3 (pl) Związki pyrazolopirymidonowe jako inhibitory kinazy
HRP20170784T8 (hr) Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora
HUE036259T2 (hu) Inhibitor vegyületek
DK2710007T3 (da) Kinasehæmmere
LT2841428T (lt) Dnr-pk inhibitoriai
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
PL3495367T3 (pl) Podstawione związki tricykliczne jako inhibitory fgfr
SMT201600114B (it) Inibitori di beta-secretasi
LT2751083T (lt) Kvinolono junginys
CO6970602A2 (es) Inhibidores de quinasa
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
CO6862160A2 (es) Indazoles
BR112014002399A2 (pt) conjunto
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
BR112014012016A2 (pt) compostos
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
EP2765427A4 (en) Probe unit
IL231616A0 (en) Tropicalizing agent
BR112013025761A2 (pt) inibidores de hsp90